Jeuveau / Nabota
Jeuveau and Nabota are regional names connected to the same Daewoong-origin botulinum toxin type A product family. Daewoong Pharmaceutical developed and manufactures the product; Evolus commercializes it as Jeuveau in the United States, while Nabota remains the central Korean and export-associated product name.
In the United States, Jeuveau interpretation should stay anchored to the Jeuveau prescribing information rather than to Nabota or other regional names. Shared product origin does not create one universal label, indication set, vial presentation, or approval status.
Jeuveau matters because it links Korean toxin manufacturing, U.S. aesthetic commercialization, and the competitive expansion of type A brands beyond the older Botox, Dysport, and Xeomin reference set.
Product Identity
Section titled “Product Identity”| Field | Reference point |
|---|---|
| U.S. brand | Jeuveau |
| Nonproprietary name | PrabotulinumtoxinA-xvfs |
| Toxin type | Botulinum toxin type A |
| Developer and physical manufacturer | Daewoong Pharmaceutical |
| U.S. license holder and commercial company | Evolus |
| Related names | Nabota; Nuceiva in selected markets |
Label Context
Section titled “Label Context”The U.S. prescribing information lists Jeuveau for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
That label anchor is narrow and product-specific. Nabota, Jeuveau, Nuceiva, and other regional naming contexts should not be treated as one universal approval profile.
Market Interpretation
Section titled “Market Interpretation”Jeuveau is often discussed as a newer aesthetic-market peer to Botox, Dysport, Xeomin, Daxxify, and Letybo. The comparison is useful at the market level, but it should not become a conversion chart or a ranking claim.
The Daewoong / Nabota connection also makes Jeuveau important to company-level interpretation. It sits near Hugel and Medytox in the Korean manufacturer graph, while its U.S. label and commercialization pathway are distinct.
David Moatazedi provides the Evolus leadership context for Jeuveau / Nuceiva commercialization, while Daewoong remains the product-origin and manufacturing node.
Legal and Commercial Context
Section titled “Legal and Commercial Context”Daewoong, Evolus, Medytox, and AbbVie / Allergan have been connected through well-known U.S. trade-secret and settlement history. That history shaped market access and company relationships. It does not establish that one botulinum toxin product is clinically superior, safer, longer-lasting, or unit-equivalent to another.